Relapse risk after Discontinuation of Antidepressants during Pregnancy (R-DAP study)

怀孕期间停用抗抑郁药后复发的风险（R-DAP 研究）

基本信息

批准号：
10569044
负责人：
Veerle Bergink
金额：
$ 55.2万
依托单位：
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-03-02 至 2024-01-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10569044
关键词：
Adverse effects Antidepressive Agents Anxiety Disorders Bipolar Disorder Birth Child Conceptions Decision Making Depressive disorder Emotions Endocrine Event Exposure to Fathers Female Fetal Development Fetus General Population Genetic Genetic Predisposition to Disease Genetic study Goals Health Immune Investigation Life Long-Term Effects Mental Depression Mental Health Mental disorders Mood Disorders Moods Mothers Outcome Outpatients Perinatal Pharmaceutical Preparations Physiology Population Postpartum Period Pregnancy Pregnant Women Process Psychiatric therapeutic procedure Relapse Reporting Residual state Resources Risk Risk Factors Risk Reduction Sample Size Sampling Schizophrenia Self-Injurious Behavior Severities Siblings Sleep Deprivation Suicide Suicide attempt Time Woman Work aged antidepressant effect genetic information health of the mother in utero interest maternal depression men offspring perinatal period peripartum depression pharmacologic polygenic risk score population based predictive modeling prenatal exposure relapse risk reproductive secondary outcome tool unborn child

项目摘要

Project Summary Over the past decades, the use of antidepressants (ADs) as first-line treatment for both depressive and anxiety disorders has increased exponentially, with females in their reproductive years using ADs twice as often as men. Prior to conception or during pregnancy, approximately 50% of women on ADs (200,000 pregnant women in the US each year) decide to discontinue their medication. While the wish to avoid in utero AD exposure to the fetus is understandable, discontinuation of medication might lead to relapse, which can have a profound negative impact on the health of mother and child. Unfortunately, general information on relapse risks after AD discontinuation cannot be used during pregnancy and the postpartum period given the enormous changes in physiology and emotion. Further, women discontinue AD prior to or during pregnancy regardless of their mood stability, which has an impact on relapse risk. Only three small studies in highly selected populations have investigated relapse risks during pregnancy and not a single study on AD discontinuation during pregnancy has investigated the relapse risk postpartum. This study will quantify the relapse risk during pregnancy and postpartum after AD discontinuation, for the first time, in a large and representative population sample. We will use the unique Danish national longitudinal registers covering medication use since 1995 in the entire female population giving birth aged 15-49 years (N=1,098,137). With our sample size, we will be able to identify both pregnancy specific and non-pregnancy specific risk factors for relapse and timing to relapse. We will determine to which extent the perinatal period is different in terms of relapse risks after AD discontinuation compared to other periods in a woman’s life. In addition, we will explore if women with high genetic susceptibility for mood-disorders are more vulnerable for relapse after AD discontinuation. In our last aim we will determine the long-term effects (up to 24 years) of maternal relapse during pregnancy and the postpartum period on the offspring. We will conduct a sibling comparison, in which we compare the health outcomes in children exposed to maternal relapse to their siblings not exposed to maternal relapse in the perinatal period. We will explore if polygenic risk scores of the children influence the association between their exposure to maternal relapse and their long-term psychiatric outcome, considering in utero exposure to AD medication.

项目概要在过去的几十年里，抗抑郁药（AD）作为抑郁症和焦虑症的一线治疗方法疾病呈指数级增长，育龄女性使用 AD 的频率是男性的两倍。在受孕之前或怀孕期间，大约 50% 的女性服用 AD（200,000 名孕妇）美国每年）决定停止用药，同时希望避免胎儿在子宫内暴露于AD。可以理解，停药可能会导致复发，这可能会产生深远的负面影响不幸的是，AD 后复发风险的一般信息。鉴于妊娠期和产后的巨大变化，不能停药。此外，无论情绪如何，女性在怀孕前或怀孕期间都会停止 AD。稳定性，这对复发风险有影响，只有三项针对精心挑选的人群的小型研究得出了这一结论。调查了怀孕期间的复发风险，但没有一项关于怀孕期间 AD 停药的研究调查产后复发风险。这项研究将量化 AD 停药后怀孕期间和产后的复发风险，我们将首次在大量且具有代表性的人口样本中使用独特的丹麦国家纵向。登记册涵盖自 1995 年以来所有 15-49 岁生育女性人口的药物使用情况（N=1,098,137）根据我们的样本量，我们将能够识别妊娠特异性和非妊娠性。复发的具体危险因素和复发时间我们将确定围产期的程度。与女性生命中的其他时期相比，AD 停药后的复发风险有所不同。此外，我们将探讨对情绪障碍具有高遗传易感性的女性是否更容易受到情绪障碍的影响。在我们的最后一个目标中，我们将确定 AD 停药后的长期影响（长达 24 年）。母亲在怀孕期间和产后复发对后代我们将进行兄弟姐妹。比较，其中我们将遭受母亲复发的儿童的健康结果与其兄弟姐妹进行比较在围产期未暴露于母亲复发的情况下，我们将探讨儿童的多基因风险评分。影响她们的孕产妇复发情况与其长期精神病结果之间的关联，考虑在子宫内接触 AD 药物。